An interventional study of DECISIVE in Peritoneal Cancer, sponsored by Yale University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Yale University · Not applicable, Interventional, and Supportive care
The purpose of this study is to evaluate the provided educational material and decision-making support related to cytoreductive surgery.
Participants will be given either standard of care or a website-based educational tool regarding cytoreductive surgery and complete an online pre-operative survey, 6 week follow up Zoom interview and two online post-operative surveys at 6 weeks and 6 months.
Yale University is the lead sponsor of 1,771 studies on the registry; 295 are open to participants now.
Of its 221 completed or terminated interventional studies of FDA-regulated products, 129 (58%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive the DECISIVE decision-support tool at their initial consultation for cytoreductive surgery.
Behavioral: DECISIVE
Participants given standard educational materials alone.
Decision-support tool received at initial consultation for cytoreductive surgery.
Reach
Percentage of eligible participants that were contacted, enrolled, and randomized to the tool arm who ultimately accessed the tool.
Time frame: From screening to enrollment, approximately one week
Feasibility- screen-to-enrollment ratio milestone
Achieving screen-to-enrollment ratio of \>30%
Time frame: Pre-operative (baseline) and 6 weeks post-operative
Feasibility- successful recruitment milestone
Achieving successful recruitment of at least 20 participants
Time frame: Pre-operative (baseline) and 6 weeks post-operative
Feasibility- complete follow up milestone
Achieving 90% of participants complete follow-up interviews and surveys
Time frame: Pre-operative (baseline) and 6 weeks post-operative
Mean score Acceptability of Intervention Measure (AIM)
The Acceptability of Intervention Measure (AIM) is a brief self-report measures designed to assess the extent to which an intervention is acceptable. Scores range from 8 to 40 with higher scores indicating greater acceptability (better outcome = high acceptability).
Time frame: 6 weeks and 6 months post-operative
Was It Worth It scale
3-item questionnaire used in medical and oncology research to measure a patient's perception of whether a treatment's benefits justified its side effects and burdens. Responses to each question: Yes, No or Uncertain.
Time frame: 6 weeks and 6 months post-operative
Participant satisfaction
Indicators of satisfaction or perceived usefulness of tool in thematic analysis of interview transcripts.
Time frame: 6 weeks and 6 months post-operative
Percentage of participants that achieve Informational satisfaction
Informational satisfaction defined as participants' perceived satisfaction with information received throughout their consultation for cytoreductive surgery using De novo Likert scale instrument developed for the study
Time frame: Baseline to 6 months post-operative
Participants Informational satisfaction- thematic interviews
Informational satisfaction defined as participants' perceived satisfaction with information received throughout their consultation for cytoreductive surgery via thematic analysis of interview transcripts
Time frame: Baseline to 6 months post-operative
Mean score Decision Regret Scale
5-item ool developed to measure distress or remorse after making a decision, most commonly in health care. Raw scores transformed to a standard 0 to 100 with higher scores indicating more regret.
Time frame: Baseline to 6 months post-operative
Decision regret- thematic interviews
Regret about final decision to undergo or not undergo cytoreductive surgery via thematic analysis of interview transcripts
Time frame: Baseline to 6 months post-operative
Mean score Shared Decision Making (SDM) Process Survey
Total scores 0-4 where higher scores indicate more shared decision making.
Time frame: Baseline to 6 months post-operative
Shared decision-making - thematic interviews
Degree to which clinical consultation utilized shared decision-making principles via thematic analysis of interview transcripts.
Time frame: Baseline to 6 months post-operative
Mean score Functional Assessment of Cancer Therapy - General - 7 Item Version (FACT-G7)
7-item patient-reported quality-of-life measure designed for oncology research and clinical practice. Total score range 0 to 28 with higher scores indicating a better quality of life.
Time frame: Baseline to 6 months post-operative
Quality of life - thematic interviews
Participant-reported perception of quality of life via thematic analysis of interview transcripts.
Time frame: Baseline to 6 months post-operative
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Nov 2027, 12 months later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.